The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide is a four-part series focusing on what front-line providers treating patients with Type 2 diabetes and obesity can do to help their patients avoid the serious consequences of severe, progressive Fatty Liver disease. This episode looks in detail at the thinking that underlies creation of these guidelines and the key issues for practitioners to keep in mind when managing patients.
The panelists include four authors of the guidelines: first author Dr. Ken Cusi from the University of Florida, third author Dr. Diana Barb, also from the University of Florida, and the two leading AASLD representatives in this project, Dr. Zobair Younossi of INOVA Health Systems and Dr. Maru Rinella of the University of Chicago. Dr. Younossi focuses his discussion on the epidemiology of the disease and what it suggests in terms of treatment goals and priorities. Dr. Cusi identifies the two main messages of the guidelines: the importance of FIB-4 as a screening tool and the fact that even today, with no recently approved NASH drugs on the market, there are therapeutic choices providers can make that will benefit NASH patients. Dr. Barb. discusses in detail prescribing decisions that can benefit diabetes patients at risk of progressing to significant NASH fibrosis or worse. Dr. Rinella lends comments throughout from her own perspective and that of AASLD. This fast-paced episode provides a tremendous amount of information while remaining accessile and easy to follow.
This podcast series and all the episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only and should not be taken as medical advice.